Results for
"[search-keyword]"
Sponsor content
162 result(s) found, displaying 21 to 30
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for WEZLANA ustekinumab 45 mg / 0.5 mL solution for subcutaneous injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for WEZLANA ustekinumab 5 mg / 1.0 mL (130 mg/26 mL) solution for intravenous infusion injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for WEZLANA ustekinumab 45 mg / 0.5 mL solution for subcutaneous injection pre-filled syringe.
-
May-2024Prescription medicine evaluationActive ingredient: inebilizumab.
-
Designation or determinationProvisional determination
-
Apr-2024Prescription medicine evaluationActive ingredient: teprotumumab.
-
-
-
Feb-2024Prescription medicine evaluationActive ingredient: blinatumomab.
-
Prescription medicine decision summaryWezlana (ustekinumab) has been approved for the treatment of plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.